Loader

Please wait...

Canadian Pharmacists Association Logo
Canadian Pharmacists Association Logo
Share
Facebook Share
Twitter Share
LinkedIn Share
Google Plus Share
Email Share

Communications with Government

CPhA is dedicated to ensuring that the voice of the profession is heard at the national level. We communicate with the federal government on a regular basis, submitting position statements, offering support and expertise and presenting to parliamentary committees on issues affecting pharmacists and the health and safety of Canadians.

October 2016
Opioid Crisis in Canada — Standing Committee on Health
Alistair Bursey, Chair, and Phil Emberley, Director of Professional Affairs, appeared before the House of Commons Standing Committee on Health as part of its study on the Opioid Crisis in Canada.
Read the speaking notes

October 2016
Letter to Minister of Health on Health Accord Priorities
CPhA sent a letter to the Honourable Jane Philpott, Minister of Health, outlining its priorities for a new Health Accord, including improving drug access, investing in innovation and ensuring fairness for Canada's Indigenous peoples.
Read the letter

August 2016
Task Force on Marijuana Legalization and Regulation
CPhA submitted a brief in response to the issues outlined in the Task Force’s recent discussion paper (‘Toward the Legalization, Regulation and Restriction of Access to Marijuana’). The submission outlines CPhA’s priorities and recommendations for the legalization and regulation of marijuana, informed by research and consultation. CPhA is focused on improving the existing framework for medical cannabis through pharmacist management and dispensing. The submission also makes public health-focused recommendations to inform the legalization of recreational marijuana.
Read the submission

August 2016
Federal Pre-Budget Consultation
CPhA submitted a brief to the federal pre-budget consultation highlighting three priorities for the 2017 federal budget to improve the health of Canadians. The recommendations focus on investing in optimal drug therapy for Canadians and enhancing drug access; educating Canadians about the health impacts of marijuana use, particularly as it relates to the medical use of marijuana and the risk of potential drug interactions; and improving health care for indigenous peoples through enhanced drug access and pharmacist services.
Read the submission

May 2016
Letter to Minister of Health on Medical Marijuana Regulations
CPhA sent a letter to the Honourable Jane Philpott, Minister of Health, urging the government to consider including amendments to the Marihuana for Medical Purposes Regulations (MMPR) to allow pharmacists to dispense medical marijuana.
Read the letter

May 2016
Pharmacare — Standing Committee on Health
Perry Eisenschmid, CEO, and Phil Emberley, Director of Professional Affairs, appeared before the House of Commons Standing Committee on Health as part of its study on the development of a national pharmacare program.
Read the speaking notes

May 2016
Assisted Dying — Standing Senate Committee on Legal and Constitutional Affairs
Phil Emberley, Director of Professional Affairs, appeared before the Standing Senate Committee on Legal and Constitutional Affairs to testify on Bill C-14, An Act to amend the Criminal Code and to make related amendments to other Acts (medical assistance in dying).
Read the speaking notes

May 2016
Assisted Dying — Standing Committee on Justice and Human Rights
Phil Emberley, Director of Professional Affairs, appeared before the House of Commons Standing Committee on Justice and Human Rights to testify on Bill C-14, An Act to amend the Criminal Code and to make related amendments to other Acts (medical assistance in dying).
Read the speaking notes

February 2016
Federal Pre-Budget Consultation
CPhA submitted a brief to the federal pre-budget consultation highlighting three priorities for the 2016 federal budget to improve the health of Canadians, including improving drug access, the implementation of a national plan for e-prescribing and the development of a strengthened National Immunization Strategy.
Read the submission

January 2016
Special Joint Committee on Physician-Assisted Dying (PDAM)
Carlo Berardi, Chair, Canadian Pharmacists Association, and Phil Emberley, Director of Professional Affairs, appeared before the Special Committee on Physician-Assisted Dying to represent the views of the pharmacist profession and discuss key pharmacy considerations, including drug access, protection of conscience, liability of health care professionals, oversight and appropriate support for pharmacists.
Read the submission
Read the speaking notes

January 2016
Open Letter to Health Ministers
Ahead of the January 2016 F/P/T Health Ministers meeting in Vancouver, CPhA and its provincial pharmacy associations have released a joint, open letter to the Health Ministers which we hope will inform the discussion. The letter reiterates the important role of pharmacists as front line health care providers and highlights 3 issues of importance for pharmacists across the country, including drug access, assisted dying and prescription drug abuse.
Read the letter

November 2015
Assisted Dying External Panel on Options for a Legislative Response to Carter v. Canada
Recognizing that the Supreme Court Decision in Carter v. Canada has important pharmacy practice implications, CPhA has been working with its members to ensure that Canadian pharmacists views and perspectives are represented in future legislation. A survey conducted by CPhA in October showed that the community sees a vital role for pharmacists but want rights of conscience protected. As such, CPhA participated in the Expert Panel consultations to highlight early considerations in the development of legislation as it pertains to pharmacy practice.
Read the submission
View survey results

August 2015
CPhA  response to the pre-consultation notice regarding Proposed Tamper-Resistant Properties of Drugs Regulations, as published June 27, 2015 in the Canada Gazette.
Read the letter
Read CPhA 2014 submission

March 2015
Bill S4, An Act to Amend the Personal Information Protection and Electronic Documents Act (PIPEDA) — House of Commons Standing Committee on Industry, Science and Technology
Janet Cooper, Vice President, Professional Affairs, appeared before the House of Commons Standing Committee on Industry, Science and Technology to discuss Bill S-4, An Act to amend the Personal Information Protection and Electronic Documents Act (PIPEDA).
Read the speaking notes

November 2014
E-cigarettes — House of Commons Standing Committee on Health
Glen Doucet, Vice President, Advocacy & Public Affairs, and Barry Power, consulting pharmacist, appeared before the House of Commons Standing Committee on Health as part of the committee’s hearings into the issue of e-cigarettes.
Read the speaking notes
Read the submitted brief (en français)

October 2014
Bill C-17, An Act to Amend the Food and Drugs Act (Vanessa's Law) Senate Committee
Perry Eisenschmid, the Canadian Pharmacists Association's Chief Executive Officer, and Janet Cooper, Vice President, Professional and Membership Affairs, presented to the Senate Social Affairs, Science, and Technology Committee on proposed amendments to the Food and Drug Act known as Bill C-17.
Read the speaking notes in English
En francais

August 2014
Controlled Drugs and Substances Act re: tamper-resistant properties
CPhA presented a submission to Health Canada as part of its consultation on possible regulations to the Controlled Drugs and Substances Act regarding tamper resistant properties.
Read the submission
Read more about prescription drug abuse

June 2014
Prescription pharmaceuticals
Perry Eisenschmid, the Canadian Pharmacists Association's Chief Executive Officer, appeared before the Senate Social Affairs, Science, and Technology Committee for a roundtable on prescription pharmaceuticals in Canada.
Read more

June 2014
Bill C-17, An Act to Amend the Food and Drugs Act (Vanessa’s Law) House of Commons Committee
Jeff Morrison, Director, Government Relations and Public Affairs, and Barry Power, consultant, discussed Bill C-17, An Act to Amend the Food and Drugs Act (Vanessa’s Law), with the House of Commons Standing Committee on Health.
Read more

April 2014
Study of the Best Practices and Federal Barriers Related to the Scope of Practice and Skills Training of Healthcare Professionals
Speaking notes to the House of Commons Standing Committee on Health
Official transcript of the proceedings, April 10, 2014

March 2014
Study on prescription pharmaceuticals in Canada — the nature of unintended consequences
Speaking notes to the Senate Committee on Social Affairs, Science and Technology
Official transcript of the proceedings, March 26, 2014

December 2013
Prescription drug abuse
Speaking notes to the House of Commons Standing Committee on Health
Official transcript of the proceedings, December 2, 2013

March 2013
Alberta Government Cuts to Generic Drug Prices
CPhA letter to Alberta Minister of Health re: Budget cuts to generic drug prices

March 2013
Marihuana for Medical Purposes Regulations (MMPR) consultations
CPhA's response to proposed Marihuana for Medical Purposes Regulations

February 2013
Off-label use of prescription drugs
Speaking notes to the Senate Committee on Social Affairs, Science, and Technology
Offical transcript of the proceedings, February 27, 2013

May 2012
Cancellation of supplemental health benefits under the Interim Federal Health Program
Joint letter to Hon. Jason Kenney opposing cancellation of benefits

October 2011
Reviewing the 2004 Health Accord
Submission to the Senate Committee on Social Affairs, Science, and Technology

October 2011
Study on chronic disease and aging
Submission to the House of Commons Standing Committee on Health

August 2011
Pre-budget consultations
Submission to the House of Commons Finance Committee

July 2011
Medical Marihuana Consultations
Comments to Health Canada on the consultation document "Proposed
Improvements to Health Canada's Marihuana Medical Access Program"

December 2010
Application of GST/HST to professional non-dispensing pharmacy services
CPhA's request to Canada Revenue Agency for clarification of the issue
Canada Revenue Agency's Response to CPhA

October 2010
The role of pharmacists in the H1N1 pandemic and recommendations on how to improve future pandemic
Opening remarks and written brief to the Senate Committee on Social Affairs, Science and Technology

September 2010
Pan-Canadian bulk purchasing arrangement for common drugs
First Ministers’ announcement
CPhA Response to Premiers (en français)
CPhA Position Paper (2005)

August 2010
Pre-budget consultations
Submission to the House of Commons Standing Committee on Finance

July 2010
Mandatory census long form
Letter to Hon. Tony Clement

May 2010
DIDFA
CPhA Response to the Government of Ontario’s proposed regulatory changes to the
Drug Interchangeability and Dispensing Fee Act

May 2008
Review of the 10-Year Plan to Strengthen Health Care
Submission to the House of Commons Standing Committee on Health (en français)

February 2008
Post-market surveillance
Presentation to House of Commons Standing Committee on Health (en français)

March 2007
Cross-border prescription drug trade
Joint submission to the US Senate Sub-Committee

November 2006
Bill 41 – The Pharmaceutical Act
CPhA Letter of Support

November 2006
Cross-Border Prescription Drug Trade
Joint letter to Hon. Tony Clement (CPhA, OPA, CAPDM, BMC)
Joint Position Statement (CPhA, OPA, CAPDM, BMC)

November 2006
TDSPA
Submission to the Ontario Ministry of Long Term Care
Joint letter to Ontario Premier (CPhA, CACDS, CAPDM-Rx&D)